Clinical trials
Efficacy and Safety clinical trials
Below are recruiting efficacy and safety clinical trials, each written for real people, not researchers. We’re tracking 2,802 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07249879RecruitingPhase 1
CAR-T cell therapy for DLL3-positive small cell lung cancer
This trial tests a new CAR-T cell therapy (GC511B) for people with a specific type of small cell lung cancer that has DLL3 protein. The treatment uses your own immune cells to target and attack the cancer.
Beijing, Beijing MunicipalityAges 18–75 - NCT07334119RecruitingPhase 1
Testing MT-304 for advanced HER2-positive tumors
This trial tests a new drug, MT-304, for people with advanced cancers that have high levels of a protein called HER2. It aims to see if the drug is safe and helps shrink tumors.
Darlinghurst, New South WalesAges 18 years+ - NCT07404033RecruitingPhase 1
Testing a lotion for mild to moderate dandruff rash
This trial tests a new lotion for people with mild to moderate seborrheic dermatitis (a common skin condition causing red, scaly patches on the scalp, face, or chest). The study checks safety and how well the lotion works.
Suzhou, JiangsuAges 18–65 - NCT06736275RecruitingEarly Phase 1
Testing a new gene therapy for advanced solid tumors
This trial tests an experimental gene therapy called SXRN for people with advanced solid tumors that haven't responded to standard treatments. The study aims to see if it's safe and may help slow the disease.
BeijingAges 18–75 - NCT07231120RecruitingPhase 1
Testing SXRN injection for cancer-related weight loss
This trial tests a new injection called SXRN for people with advanced cancer who have lost weight and appetite (cancer cachexia). The goal is to see if it is safe and might help improve weight and appetite.
Beijing, Beijing MunicipalityAges 18–75 - NCT07368478RecruitingPhase 1
Study of BC2027 for advanced solid tumors with GPC3
This trial tests a new drug called BC2027 for people with advanced solid tumors that have a protein called GPC3. If standard treatments have stopped working, are not available, or caused side effects, this study may offer a new option.
Shanghai, Shanghai, ChinaAges 18 years+ - NCT06832982RecruitingPhase 1
Study of a new drug for advanced solid tumors
This trial tests a new drug that may help people with advanced solid tumors, including liver, stomach, and brain cancers. It is for patients whose cancer has not responded to standard treatments or who cannot have them. The study aims to find the right dose and check safety and effectiveness.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06697665RecruitingEarly Phase 1
LM103 vaccine with PD-1 for advanced solid tumors
This trial tests a new personalized cancer vaccine (LM103) combined with an immunotherapy drug (PD-1) for people with advanced solid tumors that have stopped responding to standard treatments. The goal is to see if this combination is safe and can help shrink tumors.
China, Tianjin MunicipalityAges 18–75 - NCT06618287RecruitingPhase 1/Phase 2
Testing BMS-986507 for advanced lung and breast cancers
This study tests a new drug called BMS-986507, given in different combinations, for people with advanced solid tumors (lung cancer or breast cancer that has spread). It looks at safety, how the drug works in the body, and if it helps shrink tumors.
Birmingham, AlabamaAges 18 years+ - NCT06995573RecruitingPhase 1/Phase 2
Testing a new Alzheimer's drug (NSC001) for safety and early effectiveness
This study tests a new drug called NSC001 for people with mild to moderate Alzheimer's. It checks if the drug is safe and if it might help slow memory decline. You'll need a caregiver who can join you at visits and help track your progress.
Salzburg, State of SalzburgAges 50–85 - NCT07264569RecruitingPhase 1/Phase 2
Testing a new drug for lung cancer that has spread to the brain or spinal fluid
This trial tests a new drug called BioTTT001 for people with non-small cell lung cancer (NSCLC) that has spread to the fluid around the brain or the lining of the brain (leptomeninges). The goal is to see if the drug is safe and can help control the cancer.
Zhengzhou, HenanAges 18–70 - NCT06376136RecruitingPhase 1/Phase 2
Combination therapy for advanced HER2-positive cancers
This trial tests a new combination of two drugs, BAT8010 and BAT1006, for people with advanced solid tumors that have HER2 expression. It aims to see if this combination is safe and effective for those who have run out of standard treatment options.
Guangzhou, GuangdongAges 18 years+ - NCT07073547RecruitingPhase 1
Study of AZD0120 for multiple myeloma patients
This trial tests a new drug, AZD0120, in people with multiple myeloma. It aims to find the right dose and see how safe and effective it is. The study includes both newly diagnosed and early relapsed patients.
Phoenix, ArizonaAges 18 years+ - NCT07580703RecruitingPhase 1
Brain Imaging Study for Memory and Thinking Changes
This study tests a new type of brain scan (called [18F]Flortaucipir PET) that may help detect early signs of Alzheimer's disease. Researchers want to make sure the scan is safe and works well in Chinese patients aged 50–85 with normal thinking, mild memory problems, or Alzheimer's disease.
Beijing, Beijing MunicipalityAges 50–85 - NCT05467033RecruitingPhase 3
Desmopressin to improve safety after kidney biopsy
This trial tests whether desmopressin can make kidney biopsy safer by reducing bleeding risk. It compares safety outcomes after a biopsy in people who meet specific blood, medication, and health criteria.
BialystokAges 18–99 - NCT07361237RecruitingPhase 1
HJ-004-02 tablet for EGFR-mutated lung cancer
This early-phase trial tests a once-daily tablet (HJ-004-02) for people with a specific type of lung cancer that has an EGFR mutation. It aims to see if the drug is safe and if it can shrink tumors when other treatments have stopped working.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT07055243RecruitingPhase 2
Mitapivat for red blood cell membrane disorders or CDAII
This trial tests if mitapivat, an experimental pill, can safely improve anemia and reduce symptoms like fatigue in people with inherited red blood cell membrane disorders or congenital dyserythropoietic anemia type II (CDAII). It is a proof-of-concept study to see if the drug works.
Toronto, OntarioAges 18 years+ - NCT06702449RecruitingPhase 1/Phase 2
UTI vaccine safety and immune response study for adults 18-64
This trial tests a new vaccine to prevent urinary tract infections (UTIs). It first checks safety and immune response in healthy adults, then in women with recent E. coli UTIs. The goal is to see if the vaccine can reduce future infections.
Lenexa, KansasAges 18–64
Hear when a new Efficacy and Safety trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for efficacy and safety?
- Yes. Clin2 currently lists 2,802 recruiting efficacy and safety studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a efficacy and safety trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a efficacy and safety trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.